New Research Explores the Cost of Managing Brain Metastases in ALK
New research published in Lung Cancer Management explores the economic and quality-of-life costs of managing brain metastases in ALK-positive lung cancer patients. The study aims to help health systems better understand the value of preventative care.
Why it matters
Quantifying the cost of complications helps healthcare providers and policymakers allocate resources more effectively for cancer treatment.
Oncogene Cancer Research shared on LinkedIn :
“Brain metastases are one of the complications people with ALK + and other forms of lung cancer worry about most.
New UK research puts a figure on what preventing them could mean.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in